June 2019

Posts published in June 2019

Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in one or more hematologic lines is necessary for the diagnosis of MDS. However, numerous reactive conditions other than MDS can cause cytopenia and these conditions must be distinguished from MDS. […]

Read More

Genomic Testing Cooperative Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms

palmetto covers 2 ngs tests 1200x630

GTC Receives Medicare Coverage for 2 NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms Irvine, California– June 19, 2019 – Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA (MolDx®) has finalized its review and has established coverage for two Genomic Testing Cooperative (GTC) hematology profiles: GTC-Hematology (177 gene […]

Read More

Comprehensive PIK3CA Mutation Analysis

PIK3CA Comprehensive Testing & Breast Cancer Profiling, PIK3CA

  When you order GTC Breast Cancer Profile   The FDA has approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after […]

Read More